PaxMedica is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet needs in neurodevelopmental disorders.
Our lead programs are focused on Autism Spectrum Disorder (ASD).
Autism Spectrum Disorders are characterized by extreme versions of the processes that govern the ability to (1) focus attention, and (2) filter out sensory input. While these often bring with them a wide range of special abilities — including the ability to hyperfocus on specific tasks — they also can make normal everyday interactions and activities more challenging, not only for people with autism, but also for those around them, beginning with their families.
PaxMedica’s lead product in development may help eliminate, reduce, or modulate some of the more troublesome aspects of these processes. That opens the potential for people with autism to integrate their behavior with others more successfully and improve their lives. And that would be a significant advance for them and everyone they touch — families, friends, and the larger world around them.
Human African Trypanosomiasis (HAT) is a neglected tropical disease commonly known as African sleeping sickness. It is endemic to regions of sub-Saharan Africa and is a serious disease that is fatal if not adequately treated. PaxMedica is on a path to file an NDA with the FDA in 2024 for PAX-101 for the treatment of this neglected tropical disease in the US. If approved as an orphan drug, PaxMedica may qualify to receive a Priority Review Voucher (PRV), a valuable asset to advance clinical development of PAX-101 for ASD.
David Hough shared key updates following PaxMedica's recent meeting with the FDA, highlighting pivotal achievements
Randomized clinical trial of low dose suramin intravenous infusions for treatment of autism spectrum disorder